Jennie Walgren

Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers

Sheng-Bin Peng, James R. Henry, Michael D. Kaufman et al. · Cancer Cell · 2015 · 305 citations · Full text

Ly3009120 Leads, Raf Isoforms, Medicine +8

High glucose and insulin promote<i>O-</i>GlcNAc modification of proteins, including α-tubulin

Jennie Walgren, Timothy S. Vincent, Kevin L. Schey et al. · American Journal of Physiology-Endocrinology and Metabolism · 2003 · 157 citations

High Glucose, Glycobiology, Insulin Signaling +19

ERK Inhibitor LY3214996 Targets ERK Pathway–Driven Cancers: A Therapeutic Approach Toward Precision Medicine

Shripad V. Bhagwat, William T. McMillen, Shufen Cai et al. · Molecular Cancer Therapeutics · 2019 · 101 citations · Full text

Discovery of 1-(3,3-Dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-<i>d</i>]pyrimidin-6-yl)phenyl)urea (LY3009120) as a Pan-RAF Inhibitor with Minimal Paradoxical Activation and Activity against <i>BRAF</i> or <i>RAS</i> Mutant Tumor Cells

James R. Henry, Michael D. Kaufman, Sheng-Bin Peng et al. · Journal of Medicinal Chemistry · 2015 · 84 citations · Full text

Kinase Inhibitors, Pharmaceutical Chemistry, Tumor Biology +20

Aurora A–Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy

Jian Du, Lei Yan, Raquel Torres et al. · Molecular Cancer Therapeutics · 2019 · 51 citations · Full text